Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1

Status

Recruiting 3Unknown 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Sarcoma 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 358Lung Neoplasms 195Breast Neoplasms 163Ovarian Neoplasms 129Triple Negative Breast Neoplasms 79Squamous Cell Carcinoma of Head and Neck 73Small Cell Lung Carcinoma 67Fallopian Tube Neoplasms 56Head and Neck Neoplasms 46Carcinoma, Ovarian Epithelial 44Neoplasms 40Neoplasm Metastasis 39Esophageal Neoplasms 36Adenocarcinoma of Lung 35Esophageal Squamous Cell Carcinoma 29Prostatic Neoplasms 27Endometrial Neoplasms 27Uterine Cervical Neoplasms 23Brain Neoplasms 23Central Nervous System Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Squamous Cell 21Recurrence 20Neuroblastoma 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 19Lymphoma 19Carcinoma 18Adenocarcinoma, Bronchiolo-Alveolar 18Testicular Neoplasms 15

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × Carboplatin × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Tang-Du Hospital

Phase 2 Recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡